Table 1 Clinicopathological profiles of SLC3A2High and SLC3A2Low.
From: Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas
Characteristics | Low expression of SLC3A2 | High expression of SLC3A2 | P value |
|---|---|---|---|
n | 349 | 349 | |
WHO grade, n (%) | < 0.001 | ||
G2&G3 | 243 (35%) | 168 (24.2%) | |
G4 | 104 (15%) | 180 (25.9%) | |
IDH status, n (%) | < 0.001 | ||
Mutant | 262 (38.1%) | 180 (26.2%) | |
WT | 81 (11.8%) | 165 (24%) | |
1p/19q codeletion, n (%) | 0.082 | ||
non-codel | 271 (39.2%) | 249 (36%) | |
codel | 76 (11%) | 95 (13.7%) | |
Primary therapy outcome, n (%) | 0.057 | ||
CR | 85 (18.3%) | 54 (11.6%) | |
PR | 33 (7.1%) | 32 (6.9%) | |
PD | 51 (11%) | 61 (13.1%) | |
SD | 87 (18.8%) | 61 (13.1%) | |
Histological type, n (%) | < 0.001 | ||
Astroctyoma | 176 (25.6%) | 95 (13.8%) | |
Glioblastoma | 42 (6.1%) | 204 (29.7%) | |
Oligodendroglioma | 130 (18.9%) | 41 (6%) | |
Gender, n (%) | 0.193 | ||
Male | 192 (27.5%) | 209 (29.9%) | |
Female | 157 (22.5%) | 140 (20.1%) | |
Age, n (%) | < 0.001 | ||
< = 60 | 320 (45.8%) | 235 (33.7%) | |
> 60 | 29 (4.2%) | 114 (16.3%) | |
OS event, n (%) | < 0.001 | ||
Alive | 349 (50%) | 77 (11%) | |
Dead | 0 (0%) | 272 (39%) | |
DSS event, n (%) | < 0.001 | ||
Alive | 349 (51.6%) | 84 (12.4%) | |
Dead | 0 (0%) | 244 (36%) |
